Alternatives to amphotericin B for Candida rugosa infection

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 477-480

  Hernandez, Steve ^a   Gonzalez, Gloria M ^a,b   McCarthy, Dora I ^a   Colombo, Arnaldo Lopes ^c   Najvar, Laura K ^a   Bocanegera, Rosie ^a   Graybill, John R ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antifungals; C. rugosa; Murine model

Indexed keywords

AMPHOTERICIN B; CYCLOPHOSPHAMIDE; FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA RUGOSA; CANDIDIASIS; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FUNGUS ISOLATION; IN VIVO STUDY; INOCULATION; MALE; MOUSE; NEUTROPENIA; NONHUMAN; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDIASIS; COLONY COUNT, MICROBIAL; FLUCONAZOLE; KIDNEY; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; ORGAN SIZE; PYRIMIDINES; SPLEEN; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 4444359274     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh335     Document Type: Article

References (10)

1. Pfaller, M. A., Jones, R. N., Messer, S. A. et al. (1998). National survelliance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagnostic Microbiology & Infectious Disease 31, 327-32.
2. Colombo, A. L., Perfect, J., DiNubile, M. et al. (2003). Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. European Journal of Clinical Microbiology & Infectious Diseases 22, 470-4.
3. Krcmery, V. & Barnes, A. J. (2002). Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. Journal of Hospital Infection 50, 243-60.
4. Colombo, A. L., Melo, A. S., Crespo-Rosas, R. F. et al. (2003). Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagnostic Microbiology & Infectious Disease 46, 253-7.
5. Dubé, M. P., Heseltine, P. N., Rinaldi, M. G. et al. (1994). Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clinical Infectious Diseases 18, 72-82.
6. National Committee for Clinical Laboratory Standards (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA, USA.
7. Nguyen, M. H., Clancy, C. J., Yu, V. et al. (1998). Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. Journal of Infectious Diseases 177, 425-30.
8. Powderly, W. G., Kobayashi, G. S., Herzig, G. P. et al. (1988). Amphotericin B-resistant yeast infection in severely immunocompromised patients. American Journal of Medicine 84, 826-32.
9. Damkier, P., Hansen, L. L. & Brosen, K. (1999). Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. British Journal of Clinical Pharmacology 48, 829-38.
10. Sugar, A. M. & Liu, X. P. (2001). Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrobial Agents and Chemotherapy 45, 601-4.